RecruitingPhase 2NCT06728410

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mehmet Akce
Principal Investigator
Mehmet Akce, MD, M.D
Sponsor-Investigator
Intervention
Pemigatinib(drug)
Enrollment
38 enrolled
Eligibility
18 years · All sexes
Timeline
20262027

Study locations (1)

Collaborators

AstraZeneca · Incyte Corporation · University of Alabama at Birmingham

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06728410 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma

← Back to all trials